

April 2, 2012



Boston Therapeutics Corporate Update

MANCHESTER, NH--(Marketwire -04/02/12)- Boston Therapeutics Inc. (OTC.BB:[BTHE.OB](#) - [News](#)), a developer of diabetes therapeutics, reviews the series of events that have led to the availability of its lead product SUGARDOWN®, and its status as a publicly traded company.

Boston Therapeutics submitted SUGARDOWN® structure and function claims to the US Food and Drug Administration as a novel non-systemic chewable dietary supplement that supports glycemic control and digestive health.

Following the submission to the US Food and Drug Administration, Boston Therapeutics licensed exclusive rights to commercialize SUGARDOWN® for blood sugar management in China to Advance Pharmaceutical Co. Ltd.

Last year Boston Therapeutics also completed a human clinical study with SUGARDOWN® at University of Sydney, Australia and initiated a Phase 2 Clinical Trial of PAZ320 in Type 2 Diabetes at Dartmouth-Hitchcock Medical Center, New Hampshire.

A few months ago, Boston Therapeutics received its first purchase order for sales of SUGARDOWN® in Italy and announced clinical study safety results with SUGARDOWN® at University of Sydney in Australia.

Boston Therapeutics recently received regulatory clearance to be listed on the OTC Bulletin Board and was quoted under the ticker BTHE.OB

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, is a leader in the field of glycopathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company's initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose excursion; SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement designed to moderate post-meal blood glucose; and IPOXYN™, a systemic, injectable complex carbohydrate-based oxygen therapeutic for limb ischemia.

Additional information is available at [www.bostonti.com](#) and [www.sugardown.com](#)

For more information about Boston Therapeutics, its lead OTC product, SUGARDOWN®, PAZ320, or Ipoxyntm, please visit [www.bostonti.com](#) and [www.sugardown.com](#)